Literature DB >> 21377267

Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Thomas S Uldrick1, Denise Whitby.   

Abstract

Much has been learned since the discovery of KSHV in 1994 about its epidemiology and pathology but much of what has been learned has yet to be translated into clinical practice. In this review, we survey the current state of knowledge on KSHV epidemiology and KS pathogenesis and highlight therapeutic opportunities in both the developed and developing world.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21377267      PMCID： PMC3085592          DOI： 10.1016/j.canlet.2011.02.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  141 in total

1.  Human herpesvirus-8 in northwestern China: epidemiology and characterization among blood donors.

Authors:  Xing Wang; Bin He; Zhaoxia Zhang; Tao Liu; Hui Wang; Xu Li; Qiong Zhang; Ke Lan; Xiaomei Lu; Hao Wen
Journal:  Virol J       Date:  2010-03-17       Impact factor: 4.099

2.  Development of cancer in transplantation patients.

Authors:  I Penn
Journal:  Adv Surg       Date:  1978

3.  Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex.

Authors:  N A Smith; C A Sabin; R Gopal; D Bourboulia; W Labbet; C Boshoff; D Barlow; B Band; B S Peters; A de Ruiter; D W Brown; R A Weiss; J M Best; D Whitby
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

4.  Invited commentary: determining specific sexual practices associated with human herpesvirus 8 transmission.

Authors:  J N Martin; D H Osmond
Journal:  Am J Epidemiol       Date:  2000-02-01       Impact factor: 4.897

Review 5.  KSHV after an organ transplant: should we screen?

Authors:  A G Marcelin; V Calvez; E Dussaix
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

6.  Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients.

Authors:  E T Lennette; D J Blackbourn; J A Levy
Journal:  Lancet       Date:  1996-09-28       Impact factor: 79.321

7.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

8.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors:  D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

9.  Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Authors:  Mark Bower; Tom Powles; Sarah Williams; Tom Newsom Davis; Mark Atkins; Silvia Montoto; Chloe Orkin; Andy Webb; Martin Fisher; Mark Nelson; Brian Gazzard; Justin Stebbing; Peter Kelleher
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

10.  Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.

Authors:  J Paredes; J O Kahn; W P Tong; M L Feldstein; S Lin; J M Bennett; C E Metroka; L Ratner; S E Krown
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-06-01
View more
  63 in total

Review 1.  The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.

Authors:  Mary E Ballestas; Kenneth M Kaye
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

2.  Tiled microarray identification of novel viral transcript structures and distinct transcriptional profiles during two modes of productive murine gammaherpesvirus 68 infection.

Authors:  Benson Yee Hin Cheng; Jizu Zhi; Alexis Santana; Sohail Khan; Eduardo Salinas; J Craig Forrest; Yueting Zheng; Shirin Jaggi; Janet Leatherwood; Laurie T Krug
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 3.  The horizon for treating cutaneous vascular lesions.

Authors:  Amit M Patel; Elizabeth L Chou; Laura Findeiss; Kristen M Kelly
Journal:  Semin Cutan Med Surg       Date:  2012-06

4.  Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation.

Authors:  Fabrizio Angius; Enrica Piras; Sabrina Uda; Clelia Madeddu; Roberto Serpe; Rachele Bigi; Wuguo Chen; Dirk P Dittmer; Raffaello Pompei; Angela Ingianni
Journal:  J Antibiot (Tokyo)       Date:  2017-06-14       Impact factor: 2.649

5.  Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda.

Authors:  Angela Nalwoga; Marjorie Nakibuule; Vickie Marshall; Wendell Miley; Nazzarena Labo; Stephen Cose; Denise Whitby; Robert Newton
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

6.  γ-herpesvirus latency attenuates Mycobacterium tuberculosis infection in mice.

Authors:  Halli E Miller; Kaitlin E Johnson; Vera L Tarakanova; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2019-04-30       Impact factor: 3.131

7.  Kaposi's sarcoma presenting as violaceous macules on the chest of a kidney transplanted patient.

Authors:  João Borges-Costa; Leonor Lopes; Luís Soares-Almeida; José Guerra
Journal:  BMJ Case Rep       Date:  2016-01-11

8.  High seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus (KSHV) among HIV-1-infected children and adolescents in a non-endemic population.

Authors:  Cornelia Feiterna-Sperling; Christoph Königs; Gundula Notheis; Bernd Buchholz; Renate Krüger; Katharina Weizsäcker; Josef Eberle; Nikola Hanhoff; Barbara Gärtner; Harald Heider; Detlev H Krüger; Jörg Hofmann
Journal:  Med Microbiol Immunol       Date:  2016-05-30       Impact factor: 3.402

9.  A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.

Authors:  Peter V Aka; Troy J Kemp; Charles S Rabkin; Meredith S Shiels; Mark N Polizzotto; Carmela Lauria; Francesco Vitale; Ligia A Pinto; James J Goedert
Journal:  J Infect Dis       Date:  2014-08-22       Impact factor: 5.226

10.  Cancer risk among the HIV-infected elderly in the United States.

Authors:  Elizabeth L Yanik; Hormuzd A Katki; Eric A Engels
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.